The 1st International Conference on Drug Design & Discovery: Dubai, February 3 - 6, 2008

Anti-Cancer Drug Design and Discovery

Michael J. Waring, The University of Cambridge, England
Michael J. Waring - CV - PDF

Since the date of its humble origins in an Italian harbour at the end of the Second World War cancer chemotherapy has come a long way. Dealing as it does with mankind’s most feared disease it has attracted over the years the attentions of a galaxy of brilliant, talented, thoughtful scientists, and many leads towards the discovery of new and better drugs have been pursued with varying degrees of success. Drug design, whether from de novo principles or from rational extension of established therapies, is a relatively new phenomenon. As with any other area of medicinal chemistry, serendipity or happy accident has played an important part – as indeed it did with the discovery of alkylating agents sixty years ago, or more recently the chance observation of growth inhibition by the now well-established platinum[II] compounds that have saved millions of lives. In parallel, while the discovery of antibacterial agents has totally revolutionised the treatment of infectious disease antibiotics have likewise afforded a clutch of very important drugs effective against cancer. But a quantum leap forward has occurred quite recently with the explosion of knowledge about the cell cycle and its control, mechanisms of cell signalling, hormone mechanisms, apoptosis, and oncogenes. In the latter area the discovery of cancer-predisposing and protective genes has been seminal, and now powerful tools of the new science of genomics are available to the cancer chemotherapist.

The first ICDDD to be held in Dubai in February 2008 will address all areas pertinent to this endeavour, concentrating on leads that arise from application of the new knowledge at the molecular level. To name a few, there will be presentations concerned with gene targeting, topoisomerase inhibitors, telomerase inhibitors, kinase inhibitors, histone deacetylase inhibitors, receptor blockers, angiogenesis inhibitors, metalloprotease inhibitors and hypoxia-activated agents. The list is not exhaustive and there will be plenty of room for contributions that stem from other sources, aiming to provide a well-informed and productive forum for examination of as wide a range as possible of approaches developed in disparate laboratories world-wide.

[Webmaster]   Copyright © 2007 1st International Conference on Drug Design & Discovery